ES2502790T3 - Moduladores de la cinasa Aurora y método de uso - Google Patents

Moduladores de la cinasa Aurora y método de uso Download PDF

Info

Publication number
ES2502790T3
ES2502790T3 ES11008953.9T ES11008953T ES2502790T3 ES 2502790 T3 ES2502790 T3 ES 2502790T3 ES 11008953 T ES11008953 T ES 11008953T ES 2502790 T3 ES2502790 T3 ES 2502790T3
Authority
ES
Spain
Prior art keywords
chr15
independently
formula
alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11008953.9T
Other languages
English (en)
Inventor
Stephanie D. Guens-Meyer
Vinod F. Patel
Victor J. Cee
Holly L. Deak
Bingfan Du
Brian L. Houdous
Hanh Nho Nguyen
Philipp R. Olivieri
Karina Romero
Laurie B. Schenkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/655,642 external-priority patent/US7560551B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2502790T3 publication Critical patent/ES2502790T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Abstract

Compuesto de formula I:**Fórmula** O un estereoisomero, tautórnero, solvato o sal farmaceuticamente aceptable del mismo, en la que cada uno de A1 y A2, independientemente, es N o CR9, siempre que al menos uno de A1 y A2 sea N; C1 es CR16; C2 es N o CH; D es **Fórmula** en los que D4 es NR, 0, S o CR12; D5 es N o CR2; R1 es H, OR 14 , SR 14 , OR 15 , SR 15 , NR 14 R 15 , NR 15 R 15 , (CHR15)nR14, (CHR15)nR15 0 R15, en los que n es 0, 1, 2, 3 0 4; Ria es H, CN o alquilo C1-10; alternativamente R1, tornado junto con Rla y los atomos de carbono o nitrogeno a los que estan unidos, forman un anillo de atomos de carbono parcial o completamente insaturado de 5 0 6 miembros que incluye opcionalmente 1-3 heteroatomos seleccionados de 0, N y S, y estando el anillo opcionalmente sustituido, independientemente, con 1-3 sustituyentes de oxo, R1*, SR14, 0/314, sR15, OR15, OC(0)R15, C00R15, C(0)R15, C(0)NR15R15, NR14R15 o NR 5R15; y R2 es H, halo, NO2, CN, alquilo C1_10 o alcoxilo L1 es NR15, 0, CHR15, S, C(0), S(0) o SO2; L2 es NR15, 0 o S; cada uno de R3, R4 y R9, independientemente, es H;

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67
imagen68
imagen69
imagen70
imagen71
imagen72
imagen73
imagen74
imagen75
imagen76
imagen77
imagen78
imagen79
imagen80
imagen81
imagen82
imagen83

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
ES11008953.9T 2006-01-23 2007-01-22 Moduladores de la cinasa Aurora y método de uso Active ES2502790T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76167506P 2006-01-23 2006-01-23
US761675P 2006-01-23
US655642 2007-01-18
US11/655,642 US7560551B2 (en) 2006-01-23 2007-01-18 Aurora kinase modulators and method of use

Publications (1)

Publication Number Publication Date
ES2502790T3 true ES2502790T3 (es) 2014-10-06

Family

ID=40849087

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11008953.9T Active ES2502790T3 (es) 2006-01-23 2007-01-22 Moduladores de la cinasa Aurora y método de uso

Country Status (21)

Country Link
EP (1) EP1984353B1 (es)
JP (2) JP5280862B2 (es)
KR (2) KR101300424B1 (es)
AU (2) AU2007208351C1 (es)
BR (1) BRPI0706684A2 (es)
CA (1) CA2637658C (es)
CR (1) CR10213A (es)
DK (1) DK1984353T3 (es)
EA (1) EA018128B1 (es)
ES (1) ES2502790T3 (es)
GE (1) GEP20125643B (es)
HK (1) HK1167140A1 (es)
HR (1) HRP20160039T1 (es)
HU (1) HUE028504T2 (es)
IL (1) IL192812A (es)
MA (1) MA30224B1 (es)
MY (1) MY161884A (es)
NO (1) NO20083639L (es)
NZ (1) NZ569815A (es)
TN (1) TNSN08310A1 (es)
WO (1) WO2007087276A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1984353T3 (en) * 2006-01-23 2016-03-14 Amgen Inc Aurorakinasemodulatorer and method of use
AU2008236670B2 (en) * 2007-04-05 2011-12-01 Amgen Inc. Aurora kinase modulators and method of use
ES2413806T3 (es) * 2008-03-20 2013-07-17 Amgen Inc. Moduladores de la aurora cinasa y método de uso
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20110301162A1 (en) * 2008-08-04 2011-12-08 Amgen Inc. Aurora kinase modulators and methods of use
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
CA2746307C (en) 2008-12-17 2013-11-19 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP2012529535A (ja) 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
PL2475368T3 (pl) * 2009-09-11 2015-05-29 Amgen Inc N-(4-((3-(2-amino-4-pirymidynylo)-2-pirydynylo)oksy)fenylo)-4-(4-metylo-2-tienylo)-1-ftalazynoamina do stosowania w leczeniu raka opornego na czynniki antymitotyczne
ES2543569T3 (es) 2011-03-23 2015-08-20 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
AU2014357545B2 (en) * 2013-12-03 2018-10-25 Amgen Inc. Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
MY189453A (en) 2015-06-03 2022-02-14 Bristol Myers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
AU2016325143B2 (en) 2015-09-18 2020-08-13 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
JP7032903B2 (ja) * 2016-10-12 2022-03-09 田辺三菱製薬株式会社 スルホンアミド化合物の製造方法
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN111302948A (zh) * 2020-04-13 2020-06-19 长兴进源新材料科技有限公司 一种2,2-双(4-氨基苯基)六氟丙烷合成方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511378A (ja) * 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
DE60133897D1 (de) 2000-06-28 2008-06-19 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
US6864255B2 (en) * 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
ES2333702T3 (es) 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
WO2003062225A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
EP1517904A4 (en) 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
FR2853378B1 (fr) 2003-04-02 2006-03-10 Carbone Lorraine Composants Plaquettes de frein a disque ventilees
RU2329261C2 (ru) * 2003-12-29 2008-07-20 Баниу Фармасьютикал Ко., Лтд. Новое 2-гетероарил-замещенное производное бензимидазола
CA2564355C (en) * 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
DK1984353T3 (en) * 2006-01-23 2016-03-14 Amgen Inc Aurorakinasemodulatorer and method of use

Also Published As

Publication number Publication date
MA30224B1 (fr) 2009-02-02
EP1984353B1 (en) 2015-12-30
IL192812A (en) 2014-06-30
WO2007087276A1 (en) 2007-08-02
IL192812A0 (en) 2009-02-11
HUE028504T2 (en) 2016-12-28
AU2007208351B2 (en) 2010-08-05
EP1984353A1 (en) 2008-10-29
AU2007208351C1 (en) 2011-07-07
JP2009528268A (ja) 2009-08-06
NO20083639L (no) 2008-10-22
KR101332975B1 (ko) 2013-11-25
NZ569815A (en) 2011-11-25
CR10213A (es) 2008-10-03
HK1167140A1 (en) 2012-11-23
HRP20160039T1 (hr) 2016-02-12
AU2007208351A1 (en) 2007-08-02
CA2637658A1 (en) 2007-08-02
KR20110133056A (ko) 2011-12-09
TNSN08310A1 (en) 2009-12-29
DK1984353T3 (en) 2016-03-14
MY161884A (en) 2017-05-15
JP2013136585A (ja) 2013-07-11
GEP20125643B (en) 2012-09-25
KR101300424B1 (ko) 2013-08-26
EA200801732A1 (ru) 2009-02-27
JP5753546B2 (ja) 2015-07-22
BRPI0706684A2 (pt) 2011-04-05
AU2010241280B2 (en) 2013-02-28
JP5280862B2 (ja) 2013-09-04
CA2637658C (en) 2012-07-17
AU2010241280A1 (en) 2010-11-25
KR20080095889A (ko) 2008-10-29
EA018128B1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
ES2502790T3 (es) Moduladores de la cinasa Aurora y método de uso
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
AR057987A1 (es) Compuestos agonistas de cb1 (receptor cannabinoide)
CO6270228A2 (es) Derivados de quinazilinona 6-, 7-, u 8 -sustituidos y composiciones que los comprenden y metodos para usar los mismos
ES2570745T3 (es) Aza-heterociclos bicíclicos y su uso
ES2222336T3 (es) Inhibidores de girasas y sus usos.
AR054212A1 (es) Derivados de bisarilurea sustituidos con heterociclos, composicion farmaceutica y un metodo para prepararla y compuestos intermediarios de sintesis
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
CO5601027A2 (es) Derivados de imidazol-4-il-etinil-piridina
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
RS53153B (en) ANTAGONISTS OF HYSTAMINE -3 RECEPTORS
AR069435A1 (es) Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa
AR053994A1 (es) Sulfonilpirrolidinas sustituidas procedimiento para su preparacion y su uso como medicamentos
AR048523A1 (es) Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
AR016499A1 (es) Compuestos de pirrolo[2,3-d]pirimidina, composiciones y procesos para su uso en medicina.
HRP20100283T8 (en) Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
RS50378B (sr) N-heterociklični derivati kao nos inhibitori
AR068054A1 (es) Compuestos de pirrolopirimidina
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
AR066561A1 (es) Derivados de imidazol, composiciones farmaceuticas y usos